Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | SORD | Q00796 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115242 | 1.00 | KDM4E (0.35) | KDM4EALDH1A1PKMOPRK1CDK2 | |
| SCHEMBL2115939 | 0.90 | ALDH1A1 (0.36) | KDM4EALDH1A1OPRK1MAPTPIK3CD | |
| SCHEMBL2115940 | 0.90 | ALDH1A1 (0.36) | KDM4EALDH1A1OPRK1MAPTPIK3CD | |
| SCHEMBL2115342 | 0.88 | OPRK1 (0.38) | KDM4EALDH1A1PKMOPRK1MAPT | |
| SCHEMBL2115344 | 0.88 | OPRK1 (0.38) | KDM4EALDH1A1PKMOPRK1MAPT | |
| SCHEMBL2118091 | 0.88 | PIK3CD (0.35) | OPRK1CDK2DPP4PIK3CDPIK3R1 | |
| SCHEMBL2118093 | 0.88 | PIK3CD (0.35) | OPRK1CDK2DPP4PIK3CDPIK3R1 | |
| SCHEMBL2114696 | 0.85 | P2RX3 (0.38) | OPRK1PIK3CD | |
| SCHEMBL2114702 | 0.85 | P2RX3 (0.38) | OPRK1PIK3CD | |
| SCHEMBL2114289 | 0.84 | MEN1 (0.35) | OPRK1PIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | claimed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | KDM4E 3834/4885ALDH1A1 1059/4885PKM 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.